Anidulafungin/Fluconazole
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia
Trial Timeline
Dec 1, 2010 → Nov 1, 2011
NCT ID
NCT01176058About Anidulafungin/Fluconazole
Anidulafungin/Fluconazole is a phase 3 stage product being developed by Pfizer for Candidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01176058. Target conditions include Candidemia.
What happened to similar drugs?
4 of 7 similar drugs in Candidemia were approved
Approved (4) Terminated (1) Active (3)
🔄Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01176058 | Phase 3 | Terminated |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 43 |
| Micafungin | Astellas Pharma | Approved | 35 |
| AmBisome | Gilead Sciences | Approved | 43 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 43 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 40 |
| Anidulafungin | Pfizer | Phase 3 | 40 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 41 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |